THDB(SH:600867)2017-10-25 16:00Financial Performance - Operating income for the first nine months rose by 25.28% to CNY 1,852,651,393.87 compared to the same period last year[6] - Net profit attributable to shareholders increased by 29.60% to CNY 648,588,687.78 compared to the same period last year[6] - The net profit attributable to the parent company's owners for the period reached ¥648,588,687.78, representing a 29.60% increase compared to ¥500,469,547.03 in the same period last year[14] - Total revenue for the third quarter of 2017 reached ¥671,081,296.19, an increase of 14.1% compared to ¥588,362,743.56 in the same period last year[32] - Operating profit for the third quarter was ¥281,792,850.54, up 27.4% from ¥221,369,506.29 year-over-year[33] - The net profit for the first nine months of 2017 reached ¥631,965,895.10, up 23.5% from ¥511,687,915.82 in the same period last year[38] - The total profit for Q3 2017 was ¥270,808,181.38, an increase of 18.8% from ¥228,013,428.20 in Q3 2016[38] Assets and Liabilities - Total assets increased by 3.78% to CNY 4,851,941,351.68 compared to the end of the previous year[6] - The total assets as of September 30, 2017, amounted to ¥4,851,941,351.68, compared to ¥4,675,008,486.91 at the beginning of the year[23] - The total liabilities decreased to ¥496,036,386.28 from ¥729,762,963.55, showing a reduction in financial obligations[25] - Current liabilities decreased to ¥338,028,460.50 from ¥524,917,822.98 at the beginning of the year, a reduction of 35.5%[28] - The total equity attributable to shareholders increased to ¥4,445,271,524.07 from ¥4,051,242,504.79, a rise of 9.7%[28] Cash Flow - Net cash flow from operating activities increased by 30.98% to CNY 737,906,316.45 compared to the same period last year[6] - The net cash flow from operating activities was ¥737,906,316.45, up 30.98% from ¥563,367,662.62, driven by increased sales collections in the pharmaceutical and real estate sectors[17] - The investment activities generated a net cash flow of -¥93,940,069.77, an improvement from -¥429,985,197.58, due to reduced capital expenditures on insulin analog production facilities[18] - The total cash inflow from investment activities was RMB 1,321,195,439.21, significantly higher than RMB 4,825,985.00 in the previous year[42] - The net cash flow from investment activities was negative at RMB -93,940,069.77, an improvement from RMB -429,985,197.58 in the same period last year[42] - Cash inflow from financing activities totaled RMB 562,068,395.98, down from RMB 1,805,153,968.59 in the previous year[42] - The net cash flow from financing activities was negative at RMB -527,031,258.66, compared to a positive RMB 325,743,657.41 in the same period last year[42] Expenses - Operating expenses increased by 35.60% to ¥182,409,565.21 from ¥134,518,762.49, primarily due to increased amortization of intangible assets and R&D expenses[14] - Sales expenses rose by 21.15% to ¥411,725,352.61 from ¥339,838,175.08, reflecting increased investment in market expansion for the recombinant human insulin products[14] - The company's sales expenses for the first nine months of 2017 were ¥410,335,591.83, up from ¥338,184,109.83 in the same period last year, indicating a 21.4% increase[38] - The financial expenses decreased significantly by 66.55% to ¥13,345,902.77 from ¥39,893,565.70, attributed to a reduction in short-term loan limits[14] - The company's operating costs for the third quarter were ¥384,486,688.20, up 4.0% from ¥367,498,832.95 in the same quarter last year[32] - The company's financial expenses decreased significantly to ¥4,113,853.14 in Q3 2017 from ¥14,204,960.37 in Q3 2016, a reduction of 71.0%[38] Investments - The company made an additional investment of CNY 15 million in Zhejiang Kailite Medical Equipment Co., Ltd.[12] - The company invested RMB 1,215,000,000.00 in investment activities, a significant increase from RMB 38,912,965.00 in the previous year[42] - The company reported an investment loss of ¥4,807,470.30 in Q3 2017, compared to a gain of ¥505,595.68 in Q3 2016[38] Market Strategy - The company plans to continue expanding its market share in the recombinant human insulin sector, which has shown significant revenue growth compared to the previous year[15]